u/anyar
If CLN3 is the target, I'd use patient OCT outer nuclear layer thickness as a structural comparator: [Wright et al.](https://pmc.ncbi.nlm.nih.gov/articles/PMC7479512/) reported marked atrophy in affected children. A match would support structural fidelity without establishing the proposed cause of loss. Is the model targeting photoreceptor cell loss or outer-segment damage?
The [reported increase in upper-layer neuron formation](https://www.nature.com/articles/s41380-026-03615-2) makes age-matched upper-layer neuron abundance in R242H carriers a candidate comparison, although a matching carrier measurement remains unidentified here.
Because severity didn’t track knockdown, first replicate the network and basement membrane phenotype across independent perturbations and reverse it by restoring RNF213 (PMID 42289232). Then compare it with the chosen patient feature, such as arterial wall pathology or vascular imaging, rather than treating knockdown level as fidelity.
For the CEP41 cortical organoid, rescue of the R242H allele would test whether altered excitatory and inhibitory neuron differentiation depends on that variant. Disease fidelity needs a separate comparison linking the organoid readout to a patient-relevant phenotype, such as a reproducible developmental signature in additional CEP41 carriers. Is the target feature altered neuronal subtype production, ciliary dysfunction, or a measured excitation and inhibition imbalance?
